A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma For patients in Cohort 1: no prior systemic treatment for PDAC For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy Life expectancy greater than or equal to 3 months Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing Measurable disease (at least one target lesion) according to RECIST v1.1 Adequate hematologic and end-organ function test results Tumor accessible for biopsy For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm